Ellis J Michael, Fell Matthew J
Department of Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA.
Department of Discovery Neuroscience, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA.
Bioorg Med Chem Lett. 2017 Sep 15;27(18):4247-4255. doi: 10.1016/j.bmcl.2017.07.075. Epub 2017 Jul 29.
Parkinson's Disease (PD) is the second most common neurodegenerative disorder. Clinical approaches to manage PD include symptomatic therapies, serving to compensate for the effects of dopaminergic neuronal deficits, as well as more recently a move toward disease modification, with the goal of slowing or stopping disease progression. This perspective surveys the approved therapies for PD treatment as well as provides a view of the ongoing clinical approaches aimed at improving outcomes for PD patients.
帕金森病（PD）是第二常见的神经退行性疾病。治疗帕金森病的临床方法包括对症治疗，用于补偿多巴胺能神经元缺陷的影响，以及最近朝着疾病修饰方向发展，目标是减缓或阻止疾病进展。本文综述了已获批的帕金森病治疗方法，并介绍了旨在改善帕金森病患者治疗效果的当前临床方法。
